OvaScience to Host First Quarter 2016 Financial Results Conference Call

WALTHAM, Mass.–(BUSINESS WIRE)–OvaScienceSM (NASDAQ: OVAS), a global fertility company
focused on the discovery, development and commercialization of new
treatment options, announced today that it will host a conference call
at 4:30 p.m. EDT on Thursday, May 5, 2016 to discuss first quarter 2016
financial results and provide a general corporate update.

The live call can be accessed by dialing +1 888 424 8151 for U.S.
callers and +1 847 585 4422 for international callers five minutes prior
to the start of the call and providing the passcode 6908190. A live
webcast of the conference call will be available online from the
Investors section of the Company’s website at www.ovascience.com.

A replay of the conference call will be available from 7:00 p.m. EDT on
Thursday, May 5, 2016, through 11:59 p.m. EDT on Thursday, May 12, 2016,
and may be accessed by visiting OvaScience’s website or by dialing +1
888 843 7419 for U.S. callers and +1 630 652 3042 for international
callers. The replay access code is 6908190.

About OvaScience

OvaScience (NASDAQ: OVAS) is a global fertility company dedicated to
improving treatment options for women around the world. OvaScience is
discovering, developing and commercializing new fertility treatments
because we believe women deserve more options. Each OvaScience treatment
is based on the Company’s proprietary technology platform that leverages
the breakthrough discovery of egg precursor (EggPCSM) cells –
immature egg cells found inside the protective ovarian lining. The
AUGMENTSM treatment, a fertility option specifically designed
to improve egg health, is available in certain IVF clinics in select
international regions. OvaScience has commenced a non-commercial
preceptorship training program with the OvaPrimeSM treatment,
which could increase a woman’s egg reserve, and is developing the OvaTureSM treatment,
a potential next-generation IVF treatment that could help a woman
produce healthy, young, fertilizable eggs without hormone injections.
OvaScience treatments are not available in the U.S. For more
information, please visit www.ovascience.com
and www.augmenttreatment.com
and connect with us on Twitter
and Facebook.

Forward-Looking Statements

This press release includes forward-looking statements about the
Company’s plans for the AUGMENT treatment, OvaPrime treatment and
OvaTure treatment. Actual results may differ materially from those
indicated by these forward-looking statements as a result of various
important factors, including risks related to:
the possibility
that international IVF clinics that we work with may determine not to
provide or
continue providing the AUGMENT treatment or OvaPrime
treatment, or to delay providing such treatments, based on clinical
efficacy, safety or commercial, logistic, regulatory or other reasons;
the science underlying our treatments (including the AUGMENT, OvaPrime
and OvaTure treatments), which is unproven; our ability to obtain
regulatory approval or licenses where necessary for our treatments; our
ability to develop our treatments on the timelines we expect, if at all;
our ability to commercialize our treatments, on the timelines we expect,
if at all; as well as those risks more fully discussed in the “Risk
Factors” section of our most recently filed Quarterly Report on Form
10-Q and/or Annual Report on Form 10-K. The forward-looking statements
contained in this press release reflect our current views with respect
to future events. We anticipate that subsequent events and developments
will cause our views to change. However, while we may elect to update
these forward-looking statements in the future, we specifically disclaim
any obligation to do so. These forward-looking statements should not be
relied upon as representing our view as of any date subsequent to the
date hereof.

###

Contacts

Media and Investor Contact:
OvaScience
Rebecca
J. Peterson, 617-420-8736
rpeterson@ovascience.com